[go: up one dir, main page]

MX2015000347A - Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos. - Google Patents

Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos.

Info

Publication number
MX2015000347A
MX2015000347A MX2015000347A MX2015000347A MX2015000347A MX 2015000347 A MX2015000347 A MX 2015000347A MX 2015000347 A MX2015000347 A MX 2015000347A MX 2015000347 A MX2015000347 A MX 2015000347A MX 2015000347 A MX2015000347 A MX 2015000347A
Authority
MX
Mexico
Prior art keywords
production
methods
medicaments
pharmaceutical preparations
preparations containing
Prior art date
Application number
MX2015000347A
Other languages
English (en)
Inventor
Ulrich Bothe
Naomi Barak
Matthias Busemann
Oliver Martin Fischer
Andrea Rotgeri
Tobias Marquardt
Christian Stegmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48748225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015000347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2015000347A publication Critical patent/MX2015000347A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a inhibidores de AKR1C3 y a métodos para su preparación, su uso para el tratamiento y/o la prevención de enfermedades, así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, en especial de trastornos hemorrágicos y endometriosis.
MX2015000347A 2012-07-10 2013-07-05 Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos. MX2015000347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012211970 2012-07-10
PCT/EP2013/064257 WO2014009274A1 (de) 2012-07-10 2013-07-05 3-substituierte estra-1,3,5 (10),16-tetraen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln

Publications (1)

Publication Number Publication Date
MX2015000347A true MX2015000347A (es) 2015-04-14

Family

ID=48748225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000347A MX2015000347A (es) 2012-07-10 2013-07-05 Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos.

Country Status (27)

Country Link
US (1) US9512169B2 (es)
EP (1) EP2872524B1 (es)
JP (1) JP6196302B2 (es)
KR (1) KR20150036319A (es)
CN (1) CN104428309B (es)
AP (1) AP2014008179A0 (es)
AR (1) AR092025A1 (es)
AU (1) AU2013289344A1 (es)
BR (1) BR112015000443A2 (es)
CA (1) CA2878485A1 (es)
CL (1) CL2015000039A1 (es)
CO (1) CO7160008A2 (es)
CR (1) CR20150007A (es)
DO (1) DOP2015000005A (es)
EA (1) EA201500112A1 (es)
EC (1) ECSP15000868A (es)
ES (1) ES2603258T3 (es)
IL (1) IL236581A0 (es)
MA (1) MA37742B1 (es)
MX (1) MX2015000347A (es)
PE (1) PE20150353A1 (es)
PH (1) PH12015500062A1 (es)
TN (1) TN2015000007A1 (es)
TW (1) TW201402596A (es)
UY (1) UY34899A (es)
WO (1) WO2014009274A1 (es)
ZA (1) ZA201500920B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201500851A1 (ru) 2013-02-21 2016-02-29 Байер Фарма Акциенгезельшафт ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
CA2960630A1 (en) * 2014-09-11 2016-03-17 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en) 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
CA3047191A1 (en) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
CA3047196A1 (en) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
CN110272465A (zh) * 2019-07-15 2019-09-24 成都贝诺科成生物科技有限公司 阿比特龙衍生物、其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020097A1 (en) * 1992-03-31 1993-10-14 British Technology Group Ltd. 17-substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
KR20010006118A (ko) 1997-04-07 2001-01-26 이곤 이 버그 에스트로겐 활성을 갖는 에스트라-5(10),7-디엔
WO1999046279A2 (en) * 1998-03-11 1999-09-16 Endorecherche, Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
AR021757A1 (es) * 1998-08-07 2002-08-07 Endorech Inc Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3
EP1284272A4 (en) * 2000-04-24 2003-09-10 Kyowa Hakko Kogyo Kk ESTRA-1,3,5 (10) -TRIENE DERIVATIVES
JP2007529426A (ja) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
CA2644809A1 (en) 2006-03-02 2007-09-07 Astellas Pharma Inc. 17 .beta. hsd type 5 inhibitor
EP2099814A1 (en) 2006-11-30 2009-09-16 Solvay Pharmaceuticals GmbH Substituted estratrien derivatives as 17beta hsd inhibitors
CN101563324A (zh) 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
WO2009014150A1 (ja) 2007-07-24 2009-01-29 Astellas Pharma Inc. ベンズイミダゾール誘導体
DE102011083725A1 (de) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
US9512169B2 (en) 2016-12-06
ECSP15000868A (es) 2016-01-29
MA37742B1 (fr) 2016-12-30
AU2013289344A1 (en) 2015-02-05
JP2015522050A (ja) 2015-08-03
EP2872524B1 (de) 2016-08-24
CR20150007A (es) 2015-03-13
TW201402596A (zh) 2014-01-16
UY34899A (es) 2014-02-28
AR092025A1 (es) 2015-03-18
MA37742A1 (fr) 2016-05-31
JP6196302B2 (ja) 2017-09-13
CO7160008A2 (es) 2015-01-15
EP2872524A1 (de) 2015-05-20
PE20150353A1 (es) 2015-03-28
BR112015000443A2 (pt) 2017-06-27
ZA201500920B (en) 2017-01-25
DOP2015000005A (es) 2015-02-15
WO2014009274A1 (de) 2014-01-16
CN104428309A (zh) 2015-03-18
CA2878485A1 (en) 2014-01-16
ES2603258T3 (es) 2017-02-24
IL236581A0 (en) 2015-02-26
HK1205743A1 (en) 2015-12-24
AP2014008179A0 (en) 2014-12-31
PH12015500062A1 (en) 2015-03-02
TN2015000007A1 (en) 2016-06-29
US20150210734A1 (en) 2015-07-30
EA201500112A1 (ru) 2015-07-30
KR20150036319A (ko) 2015-04-07
CN104428309B (zh) 2016-09-14
CL2015000039A1 (es) 2015-03-27

Similar Documents

Publication Publication Date Title
PH12015500062A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
MY175804A (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
IL222120A (en) Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX2012013628A (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
MX2012013703A (es) Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2015004362A (es) Derivados de ketamina.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
IN2014DN09437A (es)
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
MX2015014907A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
IN2013MU01241A (es)
IN2013MU01240A (es)
IN2013MU01242A (es)
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)
IN2013MU01250A (es)